Top

Current Diabetes Reports

Published in:

Open Access 01-12-2019 | Type 2 Diabetes | Genetics (AP Morris, Section Editor)

Pancreatic Islet Transcriptional Enhancers and Diabetes

Author: Inês Cebola

Published in: Current Diabetes Reports | Issue 12/2019

Abstract

Purpose of Review

Common genetic variants that associate with type 2 diabetes risk are markedly enriched in pancreatic islet transcriptional enhancers. This review discusses current advances in the annotation of islet enhancer variants and their target genes.

Recent Findings

Recent methodological advances now allow genetic and functional mapping of diabetes causal variants at unprecedented resolution. Mapping of enhancer-promoter interactions in human islets has provided a unique appreciation of the complexity of islet gene regulatory processes and enabled direct association of noncoding diabetes risk variants to their target genes.

Summary

The recently improved human islet enhancer annotations constitute a framework for the interpretation of diabetes genetic signals in the context of pancreatic islet gene regulation. In the future, integration of existing and yet to come regulatory maps with genetic fine-mapping efforts and in-depth functional characterization will foster the discovery of novel diabetes molecular risk mechanisms.

Gloss BS, Dinger ME. Realizing the significance of noncoding functionality in clinical genomics. Exp Mol Med. 2018;50:97. https://doi.org/10.1038/s12276-018-0087-0.CrossRefPubMedCentral

Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155:934–47. https://doi.org/10.1016/j.cell.2013.09.053.CrossRefPubMed

Ongen H, Andersen CL, Bramsen JB, Oster B, Rasmussen MH, Ferreira PG, et al. Putative cis-regulatory drivers in colorectal cancer. Nature. 2014;512:87–90. https://doi.org/10.1038/nature13602.CrossRefPubMed

Cohen AJ, Saiakhova A, Corradin O, Luppino JM, Lovrenert K, Bartels CF, et al. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nat Commun. 2017;8:14400. https://doi.org/10.1038/ncomms14400.CrossRefPubMedPubMedCentral

Miguel-Escalada I, Pasquali L, Ferrer J. Transcriptional enhancers: functional insights and role in human disease. Curr Opin Genet Dev. 2015;33:71–6. https://doi.org/10.1016/j.gde.2015.08.009.CrossRefPubMedPubMedCentral

Weedon MN, Cebola I, Flanagan SE, et al. Recessive mutations in a distal PTF1A enhancer cause isolated pancreatic agenesis. Nat Genet. 2014;46:61–4. https://doi.org/10.1038/ng.2826.CrossRefPubMed

Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337:1190–5. https://doi.org/10.1126/science.1222794.CrossRefPubMedPubMedCentral

• Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, et al. The genetic architecture of type 2 diabetes. Nature. 2016;536:41–7. https://doi.org/10.1038/nature18642 This study demonstrates that the genetic basis of T2D arises predominantly from common noncoding variants of small effect size. CrossRefPubMedPubMedCentral

Parker SCJ, Stitzel ML, Taylor DL, Orozco JM, Erdos MR, Akiyama JA, et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A. 2013;110:17921–6. https://doi.org/10.1073/pnas.1317023110.CrossRefPubMedPubMedCentral

10.

Pasquali L, Gaulton KJ, Rodríguez-Seguí SA, Mularoni L, Miguel-Escalada I, Akerman İ, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet. 2014;46:136–43. https://doi.org/10.1038/ng.2870.CrossRefPubMedPubMedCentral

11.

Cebola I, Pasquali L. Non-coding genome functions in diabetes. J Mol Endocrinol. 2016;56:R1–R20. https://doi.org/10.1530/JME-15-0197.CrossRefPubMed

12.

Varshney A, Scott LJ, Welch RP, Erdos MR, Chines PS, Narisu N, et al. Genetic regulatory signatures underlying islet gene expression and type 2 diabetes. Proc Natl Acad Sci U S A. 2017;114:2301–6. https://doi.org/10.1073/pnas.1621192114.CrossRefPubMedPubMedCentral

13.

•• Miguel-Escalada I, Bonàs-Guarch S, Cebola I, et al. Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes. Nat Genet. 2019;51:1137–48. https://doi.org/10.1038/s41588-019-0457-0 This study provides a genome-wide map of human islet 3D chromatin interactions, linking diabetes-associated enhancers to target genes, and exemplifies the integration of islet epigenomic annotations with 3D interaction maps, eQTLs and CRISPR validations. CrossRefPubMedPubMedCentral

14.

Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105–16. https://doi.org/10.1038/ng.520.CrossRefPubMedPubMedCentral

15.

Scott RA, Lagou V, Welch RP, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44:991–1005. https://doi.org/10.1038/ng.2385.CrossRefPubMedPubMedCentral

16.

Scott RA, Scott LJ, Magi R, et al. An expanded genome-wide association study of type 2 diabetes in Europeans. Diabetes. 2017;66:2888–902. https://doi.org/10.2337/db16-1253.CrossRefPubMedPubMedCentral

17.

Aylward A, Chiou J, Okino M-L, Kadakia N, Gaulton KJ. Shared genetic risk contributes to type 1 and type 2 diabetes etiology. Hum Mol Genet. 2018. https://doi.org/10.1093/hmg/ddy314.

18.

Onengut-Gumuscu S, Chen W-M, Burren O, et al. Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet. 2015;47:381–6. https://doi.org/10.1038/ng.3245.CrossRefPubMedPubMedCentral

19.

Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10:1213–8. https://doi.org/10.1038/nmeth.2688.CrossRefPubMedPubMedCentral

20.

Khetan S, Kursawe R, Youn A, Lawlor N, Jillette A, Marquez EJ, et al. Type 2 diabetes-associated genetic variants regulate chromatin accessibility in human islets. Diabetes. 2018;67:2466–77. https://doi.org/10.2337/db18-0393.CrossRefPubMedPubMedCentral

21.

• Thurner M, van de Bunt M, Torres JM, Mahajan A, Nylander V, Bennett AJ, et al. Integration of human pancreatic islet genomic data refines regulatory mechanisms at type 2 diabetes susceptibility loci. Elife. 2018;7:1363. https://doi.org/10.7554/eLife.31977 This study showcases how integration of multiple epigenomic datasets, including DNA methylation, can be used to functionally fine-map T2D risk variants.CrossRef

22.

Greenwald WW, Chiou J, Yan J, Qiu Y, Dai N, Wang A, et al. Pancreatic islet chromatin accessibility and conformation reveals distal enhancer networks of type 2 diabetes risk. Nat Commun. 2019;10:2078. https://doi.org/10.1038/s41467-019-09975-4.CrossRefPubMedPubMedCentral

23.

Andersson R, Gebhard C, Miguel-Escalada I, et al. An atlas of active enhancers across human cell types and tissues. Nature. 2014;507:455–61. https://doi.org/10.1038/nature12787.CrossRefPubMedPubMedCentral

24.

Pradeepa MM. Causal role of histone acetylations in enhancer function. Transcription. 2017;8:40–7. https://doi.org/10.1080/21541264.2016.1253529.CrossRefPubMed

25.

•• Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018;50:1505–13. https://doi.org/10.1038/s41588-018-0241-6 This study provides the most comprehensive picture of the genetic architecture of T2D to date, uncovering 403 independent association signals. CrossRefPubMedPubMedCentral

26.

DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium, Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium, South Asian Type 2 Diabetes (SAT2D) Consortium, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet. 2014;46:234–44. https://doi.org/10.1038/ng.2897.CrossRef

27.

Liu C-T, Raghavan S, Maruthur N, Kabagambe EK, Hong J, Ng MC, et al. Trans-ethnic meta-analysis and functional annotation illuminates the genetic architecture of fasting glucose and insulin. Am J Hum Genet. 2016;99:56–75. https://doi.org/10.1016/j.ajhg.2016.05.006.CrossRefPubMedPubMedCentral

28.

Magi R, Horikoshi M, Sofer T, et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. Hum Mol Genet. 2017;26:3639–50. https://doi.org/10.1093/hmg/ddx280.CrossRefPubMedPubMedCentral

29.

Wojcik GL, Graff M, Nishimura KK, Tao R, Haessler J, Gignoux CR, et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature. 2019;570:514–8. https://doi.org/10.1038/s41586-019-1310-4.CrossRefPubMedPubMedCentral

30.

Gaulton KJ, Ferreira T, Lee Y, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015;47:1415–25. https://doi.org/10.1038/ng.3437.CrossRefPubMedPubMedCentral

31.

Horikoshi M, Mӓgi R, van de Bunt M, Surakka I, Sarin AP, Mahajan A, et al. Discovery and fine-mapping of glycaemic and obesity-related trait loci using high-density imputation. PLoS Genet. 2015;11:e1005230. https://doi.org/10.1371/journal.pgen.1005230.CrossRefPubMedPubMedCentral

32.

Bonàs-Guarch S, Guindo-Martínez M, Miguel-Escalada I, Grarup N, Sebastian D, Rodriguez-Fos E, et al. Re-analysis of public genetic data reveals a rare X-chromosomal variant associated with type 2 diabetes. Nat Commun. 2018;9:321. https://doi.org/10.1038/s41467-017-02380-9.CrossRefPubMedPubMedCentral

33.

Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate causal variants by statistical fine-mapping. Nat Rev Genet. 2018;19:491–504. https://doi.org/10.1038/s41576-018-0016-z.CrossRefPubMedPubMedCentral

34.

•• Spracklen CN, Horikoshi M, Kim YJ, et al. Identification of type 2 diabetes loci in 433,540 East Asian individuals. bioRxiv. 2019. https://doi.org/10.1101/685172 This study exemplifies the potential of studying individuals of non-European ancestry to discover new genetic loci carrying T2D risk variants.

35.

Pickrell JK. Joint analysis of functional genomic data and genome-wide association studies of 18 human traits. Am J Hum Genet. 2014;94:559–73. https://doi.org/10.1016/j.ajhg.2014.03.004.CrossRefPubMedPubMedCentral

36.

Carrat GR, Hu M, Nguyen-Tu M-S, Chabosseau P, Gaulton KJ, van de Bunt M, et al. Decreased STARD10 expression is associated with defective insulin secretion in humans and mice. Am J Hum Genet. 2017;100:238–56. https://doi.org/10.1016/j.ajhg.2017.01.011.CrossRefPubMedPubMedCentral

37.

Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, et al. The human transcription factors. Cell. 2018;172:650–65. https://doi.org/10.1016/j.cell.2018.01.029.CrossRefPubMed

38.

Slattery M, Zhou T, Yang L, Dantas Machado AC, Gordân R, Rohs R. Absence of a simple code: how transcription factors read the genome. Trends Biochem Sci. 2014;39:381–99. https://doi.org/10.1016/j.tibs.2014.07.002.CrossRefPubMedPubMedCentral

39.

Bysani M, Agren R, Davegårdh C, Volkov P, Rönn T, Unneberg P, et al. ATAC-seq reveals alterations in open chromatin in pancreatic islets from subjects with type 2 diabetes. Sci Rep. 2019;9:7785. https://doi.org/10.1038/s41598-019-44076-8.CrossRefPubMedPubMedCentral

40.

Roman TS, Cannon ME, Vadlamudi S, Buchkovich ML, Wolford BN, Welch RP, et al. A type 2 diabetes-associated functional regulatory variant in a pancreatic islet enhancer at the ADCY5 locus. Diabetes. 2017;66:2521–30. https://doi.org/10.2337/db17-0464.CrossRefPubMedPubMedCentral

41.

Lieberman-Aiden E, van Berkum NL, Williams L, Imakaev M, Ragoczy T, Telling A, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science. 2009;326:289–93. https://doi.org/10.1126/science.1181369.CrossRefPubMedPubMedCentral

42.

Beagrie RA, Scialdone A, Schueler M, Kraemer DCA, Chotalia M, Xie SQ, et al. Complex multi-enhancer contacts captured by genome architecture mapping. Nature. 2017;543:519–24. https://doi.org/10.1038/nature21411.CrossRefPubMedPubMedCentral

43.

Schmitt AD, Hu M, Ren B. Genome-wide mapping and analysis of chromosome architecture. Nat Rev Mol Cell Biol. 2016;17:743–55. https://doi.org/10.1038/nrm.2016.104.CrossRefPubMedPubMedCentral

44.

Yu M, Ren B. The three-dimensional organization of mammalian genomes. Annu Rev Cell Dev Biol. 2017;33:265–89. https://doi.org/10.1146/annurev-cellbio-100616-060531.CrossRefPubMedPubMedCentral

45.

Marti-Renom MA, Almouzni G, Bickmore WA, Bystricky K, Cavalli G, Fraser P, et al. Challenges and guidelines toward 4D nucleome data and model standards. Nat Genet. 2018;50:1352–8. https://doi.org/10.1038/s41588-018-0236-3.CrossRefPubMed

46.

• Stadhouders R, Filion GJ, Graf T. Transcription factors and 3D genome conformation in cell-fate decisions. Nature. 2019;569:345–54. https://doi.org/10.1038/s41586-019-1182-7 This review provides a comprehensive overview of the current state of the epigenomics field in the context of 3D genome architecture.CrossRefPubMed

47.

Montavon T, Soshnikova N, Mascrez B, Joye E, Thevenet L, Splinter E, et al. A regulatory archipelago controls Hox genes transcription in digits. Cell. 2011;147:1132–45. https://doi.org/10.1016/j.cell.2011.10.023.CrossRefPubMed

48.

Oudelaar AM, Davies JOJ, Hanssen LLP, Telenius JM, Schwessinger R, Liu Y, et al. Single-allele chromatin interactions identify regulatory hubs in dynamic compartmentalized domains. Nat Genet. 2018;50:1744–51. https://doi.org/10.1038/s41588-018-0253-2.CrossRefPubMedPubMedCentral

49.

Tolhuis B, Palstra RJ, Splinter E, Grosveld F, de Laat W. Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol Cell. 2002;10:1453–65.CrossRefPubMed

50.

Schmitt AD, Hu M, Jung I, Xu Z, Qiu Y, Tan CL, et al. A compendium of chromatin contact maps reveals spatially active regions in the human genome. Cell Rep. 2016;17:2042–59. https://doi.org/10.1016/j.celrep.2016.10.061.CrossRefPubMedPubMedCentral

51.

Allahyar A, Vermeulen C, Bouwman BAM, Krijger PHL, Verstegen MJAM, Geeven G, et al. Enhancer hubs and loop collisions identified from single-allele topologies. Nat Genet. 2018;50:1151–60. https://doi.org/10.1038/s41588-018-0161-5.CrossRefPubMed

52.

Delaneau O, Zazhytska M, Borel C, Giannuzzi G, Rey G, Howald C, et al. Chromatin three-dimensional interactions mediate genetic effects on gene expression. Science. 2019;364:eaat8266–12. https://doi.org/10.1126/science.aat8266.CrossRefPubMed

53.

Benazra M, Lecomte M-J, Colace C, Müller A, Machado C, Pechberty S, et al. A human beta cell line with drug inducible excision of immortalizing transgenes. Mol Metab. 2015;4:916–25. https://doi.org/10.1016/j.molmet.2015.09.008.CrossRefPubMedPubMedCentral

54.

Smemo S, Tena JJ, Kim K-H, Gamazon ER, Sakabe NJ, Gómez-Marín C, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014;507:371–5. https://doi.org/10.1038/nature13138.CrossRefPubMedPubMedCentral

55.

• Claussnitzer M, Dankel SN, Kim K-H, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med. 2015;373:895–907. https://doi.org/10.1056/NEJMoa1502214 This study combines detailed epigenomic and functional characterization of a GWAS locus. CrossRefPubMedPubMedCentral

56.

Fadista J, Vikman P, Laakso EO, Mollet IG, Esguerra JL, Taneera J, et al. Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proc Natl Acad Sci U S A. 2014;111:13924–9. https://doi.org/10.1073/pnas.1402665111.CrossRefPubMedPubMedCentral

57.

van de Bunt M, Manning Fox JE, Dai X, Barrett A, Grey C, Li L, et al. Transcript expression data from human islets links regulatory signals from genome-wide association studies for type 2 diabetes and glycemic traits to their downstream effectors. PLoS Genet. 2015;11:e1005694. https://doi.org/10.1371/journal.pgen.1005694.CrossRefPubMedPubMedCentral

58.

Khamis A, Canouil M, Siddiq A, Crouch H, Falchi M, Bulow M, et al. Laser capture microdissection of human pancreatic islets reveals novel eQTLs associated with type 2 diabetes. Mol Metab. 2019;24:98–107. https://doi.org/10.1016/j.molmet.2019.03.004.CrossRefPubMedPubMedCentral

59.

• Viñuela A, Varshney A, van de Bunt M, et al. Influence of genetic variants on gene expression in human pancreatic islets – implications for type 2 diabetes. bioRxiv. 2019;50:1505. https://doi.org/10.1101/655670 This study provides the largest human islet eQTL dataset released to date.CrossRef

60.

Li G, Fullwood MJ, Xu H, Mulawadi FH, Velkov S, Vega V, et al. ChIA-PET tool for comprehensive chromatin interaction analysis with paired-end tag sequencing. Genome Biol. 2010;11:R22. https://doi.org/10.1186/gb-2010-11-2-r22.CrossRefPubMedPubMedCentral

61.

Mumbach MR, Rubin AJ, Flynn RA, Dai C, Khavari PA, Greenleaf WJ, et al. HiChIP: efficient and sensitive analysis of protein-directed genome architecture. Nat Methods. 2016;13:919–22. https://doi.org/10.1038/nmeth.3999.CrossRefPubMedPubMedCentral

62.

Jian X, Felsenfeld G. Insulin promoter in human pancreatic β cells contacts diabetes susceptibility loci and regulates genes affecting insulin metabolism. Proc Natl Acad Sci U S A. 2018;115:E4633–41. https://doi.org/10.1073/pnas.1803146115.CrossRefPubMedPubMedCentral

63.

Lawlor N, Márquez EJ, Orchard P, Narisu N, Shamim MS, Thibodeau A, et al. Multiomic profiling identifies cis-regulatory networks underlying human pancreatic β cell identity and function. Cell Rep. 2019;26:788–801.e6. https://doi.org/10.1016/j.celrep.2018.12.083.CrossRefPubMedPubMedCentral

64.

Schoenfelder S, Furlan-Magaril M, Mifsud B, Tavares-Cadete F, Sugar R, Javierre BM, et al. The pluripotent regulatory circuitry connecting promoters to their long-range interacting elements. Genome Res. 2015;25:582–97. https://doi.org/10.1101/gr.185272.114.CrossRefPubMedPubMedCentral

65.

Javierre BM, Burren OS, Wilder SP, Kreuzhuber R, Hill SM, Sewitz S, et al. Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters. Cell. 2016;167:1369–1384.e19. https://doi.org/10.1016/j.cell.2016.09.037.CrossRefPubMedPubMedCentral

66.

Dov A, Abramovitch E, Warwar N, Nesher R. Diminished phosphodiesterase-8B potentiates biphasic insulin response to glucose. Endocrinology. 2008;149:741–8. https://doi.org/10.1210/en.2007-0968.CrossRefPubMed

67.

Font-Cunill B, Arnes L, Ferrer J, Sussel L, Beucher A. Long non-coding RNAs as local regulators of pancreatic islet transcription factor genes. Front Genet. 2018;9:524. https://doi.org/10.3389/fgene.2018.00524.CrossRefPubMedPubMedCentral

68.

Jia Y, Yuan L, Hu W, Luo Y, Suo L, Yang M, et al. Zinc-finger BED domain-containing 3 (Zbed3) is a novel secreted protein associated with insulin resistance in humans. J Intern Med. 2014;275:522–33. https://doi.org/10.1111/joim.12170.CrossRefPubMed

69.

Hu W, Tian B, Li X, Li L, Zhang L, Liu H, et al. Circulating Zbed3 levels in subjects with and without metabolic syndrome. Metab Syndr Relat Disord. 2017;15:207–12. https://doi.org/10.1089/met.2016.0122.CrossRefPubMed

70.

Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518:317–30. https://doi.org/10.1038/nature14248.CrossRefPubMedCentral

71.

•• Ramos-Rodríguez M, Raurell-Villa H, Colli ML, et al The impact of pro-inflammatory cytokines on the β-cell regulatory landscape provides new insights into the genetics of type 1 diabetes. Nat Genet. 2019;51:1588–1595. doi: https://doi.org/10.1038/s41588-019-0524-6. This study demonstrates that islet regulatory landscapes are largely dynamic and responsive to stimuli. CrossRefPubMedPubMedCentral

72.

Morán I, Akerman I, van de Bunt M, Xie R, Benazra M, Nammo T, et al. Human β cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metab. 2012;16:435–48. https://doi.org/10.1016/j.cmet.2012.08.010.CrossRefPubMedPubMedCentral

73.

• Wang YJ, Kaestner KH. Single-cell RNA-Seq of the pancreatic islets--a promise not yet fulfilled? Cell Metab. 2019;29:539–44. https://doi.org/10.1016/j.cmet.2018.11.016 This review covers the currently available human islet single-cell RNA-seq datasets and sets the tone for future single-cell islet studies.CrossRefPubMed

74.

TT-H L, Heyne S, Dror E, et al. The polycomb-dependent epigenome controls β cell dysfunction, dedifferentiation, and diabetes. Cell Metab. 2018;27:1294–1308.e7. https://doi.org/10.1016/j.cmet.2018.04.013.CrossRef

75.

Volkov P, Bacos K, Ofori JK, Esguerra JLS, Eliasson L, Rönn T, et al. Whole-genome bisulfite sequencing of human pancreatic islets reveals novel differentially methylated regions in type 2 diabetes pathogenesis. Diabetes. 2017;66:1074–85. https://doi.org/10.2337/db16-0996.CrossRefPubMed

76.

Arda HE, Li L, Tsai J, Torre EA, Rosli Y, Peiris H, et al. Age-dependent pancreatic gene regulation reveals mechanisms governing human β cell function. Cell Metab. 2016;23:909–20. https://doi.org/10.1016/j.cmet.2016.04.002.CrossRefPubMedPubMedCentral

77.

Grapin-Botton A, Serup P. Parsing the pancreas. N Engl J Med. 2017;376:886–8. https://doi.org/10.1056/NEJMcibr1616217.CrossRefPubMed

78.

Dorrell C, Schug J, Canaday PS, Russ HA, Tarlow BD, Grompe MT, et al. Human islets contain four distinct subtypes of β cells. Nat Commun. 2016;7:11756. https://doi.org/10.1038/ncomms11756.CrossRefPubMedPubMedCentral

79.

Johnston NR, Mitchell RK, Haythorne E, Pessoa MP, Semplici F, Ferrer J, et al. Beta cell hubs dictate pancreatic islet responses to glucose. Cell Metab. 2016;24:389–401. https://doi.org/10.1016/j.cmet.2016.06.020.CrossRefPubMedPubMedCentral

80.

Gutierrez GD, Gromada J, Sussel L. Heterogeneity of the pancreatic beta cell. Front Genet. 2017;8:3853. https://doi.org/10.3389/fgene.2017.00022.CrossRef

81.

Ackermann AM, Wang Z, Schug J, Naji A, Kaestner KH. Integration of ATAC-seq and RNA-seq identifies human alpha cell and beta cell signature genes. Mol Metab. 2016;5:233–44. https://doi.org/10.1016/j.molmet.2016.01.002.CrossRefPubMedPubMedCentral

82.

Farack L, Golan M, Egozi A, Dezorella N, Bahar Halpern K, Ben-Moshe S, et al. Transcriptional heterogeneity of beta cells in the intact pancreas. Dev Cell. 2019;48:115–125.e4. https://doi.org/10.1016/j.devcel.2018.11.001.CrossRefPubMed

83.

Neiman D, Moss J, Hecht M, Magenheim J, Piyanzin S, Shapiro AMJ, et al. Islet cells share promoter hypomethylation independently of expression, but exhibit cell-type-specific methylation in enhancers. Proc Natl Acad Sci U S A. 2017;114:13525–30. https://doi.org/10.1073/pnas.1713736114.CrossRefPubMedPubMedCentral

84.

•• Arda HE, Tsai J, Rosli YR, et al. A chromatin basis for cell lineage and disease risk in the human pancreas. Cell Syst. 2018;7:310–322.e4. https://doi.org/10.1016/j.cels.2018.07.007 This study provides an in-depth characterization of the regulatory landscapes of specific pancreatic cell types.CrossRefPubMed

85.

•• Chiou J, Zeng C, Cheng Z, et al. Single cell chromatin accessibility reveals pancreatic islet cell type- and state-specific regulatory programs of diabetes risk. bioRxiv. 2019;71:858. https://doi.org/10.1101/693671 This study provides the first human islet regulatory maps at single-cell resolution and demonstrates that specific T2D variants reside in cell-specific regulatory elements.CrossRef

86.

Lareau CA, Duarte FM, Chew JG, Kartha VK, Burkett ZD, Kohlway AS, et al. Droplet-based combinatorial indexing for massive-scale single-cell chromatin accessibility. Nat Biotechnol. 2019;37:916–24. https://doi.org/10.1038/s41587-019-0147-6.CrossRefPubMed

87.

Grosselin K, Durand A, Marsolier J, Poitou A, Marangoni E, Nemati F, et al. High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. Nat Genet. 2019;51:1060–6. https://doi.org/10.1038/s41588-019-0424-9.CrossRefPubMed

88.

Kaya-Okur HS, Wu SJ, Codomo CA, Pledger ES, Bryson TD, Henikoff JG, et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat Commun. 2019;10:1930. https://doi.org/10.1038/s41467-019-09982-5.CrossRefPubMedPubMedCentral

89.

• McCarthy MI. Painting a new picture of personalised medicine for diabetes. Diabetologia. 2017;60:793–9. https://doi.org/10.1007/s00125-017-4210-x This review proposes the ‘palette’ model to describe the multitude of possible diabetes disease trajectories.CrossRefPubMedPubMedCentral

90.

Marchetti P, Schulte AM, Marselli L, Schoniger E, Bugliani M, Kramer W, et al. Fostering improved human islet research: a European perspective. Diabetologia. 2019;62:212–1516. https://doi.org/10.1007/s00125-019-4911-4.CrossRef

91.

Dwivedi OP, Lehtovirta M, Hastoy B, et al. Loss of ZnT8 function protects against diabetes by enhanced insulin secretion. Nat Genet. 2019;51:1596–1606. https://doi.org/10.1038/s41588-019-0513-9.CrossRefPubMedPubMedCentral

92.

Thomsen SK, Ceroni A, van de Bunt M, Burrows C, Barrett A, Scharfmann R, et al. Systematic functional characterization of candidate causal genes for type 2 diabetes risk variants. Diabetes. 2016;65:3805–11. https://doi.org/10.2337/db16-0361.CrossRefPubMed

93.

Fang Z, Weng C, Li H, Tao R, Mai W, Liu X, et al. Single-cell heterogeneity analysis and CRISPR screen identify key β-cell-specific disease genes. Cell Rep. 2019;26:3132–3144.e7. https://doi.org/10.1016/j.celrep.2019.02.043.CrossRefPubMedPubMedCentral

94.

•• Balboa D, Prasad RB, Groop L, Otonkoski T. Genome editing of human pancreatic beta cell models: problems, possibilities and outlook. Diabetologia. 2019;50:1505. https://doi.org/10.1007/s00125-019-4908-z This review provides a very up-to-date and critical overview on applying genome editing in β cells to model diabetes genetic risk variants, 1336.CrossRef

95.

Manning AK, Hivert M-F, Scott RA, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet. 2012;44:659–69. https://doi.org/10.1038/ng.2274.CrossRefPubMedPubMedCentral

96.

Gloyn AL, Drucker DJ. Precision medicine in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6:891–900. https://doi.org/10.1016/S2213-8587(18)30052-4.CrossRefPubMed

97.

• Udler MS, Kim J, Grotthuss v M, et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med. 2018;15:e1002654. https://doi.org/10.1371/journal.pmed.1002654 This study reveals that T2D patients can be clustered into different disease mechanisms.CrossRefPubMedPubMedCentral

98.

Kycia I, Wolford BN, Huyghe JR, Fuchsberger C, Vadlamudi S, Kursawe R, et al. A common type 2 diabetes risk variant potentiates activity of an evolutionarily conserved islet stretch enhancer and increases C2CD4A and C2CD4B expression. Am J Hum Genet. 2018;102:620–35. https://doi.org/10.1016/j.ajhg.2018.02.020.CrossRefPubMedPubMedCentral

99.

Fogarty MP, Cannon ME, Vadlamudi S, Gaulton KJ, Mohlke KL. Identification of a regulatory variant that binds FOXA1 and FOXA2 at the CDC123/CAMK1D type 2 diabetes GWAS locus. PLoS Genet. 2014;10:e1004633. https://doi.org/10.1371/journal.pgen.1004633.CrossRefPubMedPubMedCentral

100.

Fogarty MP, Panhuis TM, Vadlamudi S, Buchkovich ML, Mohlke KL. Allele-specific transcriptional activity at type 2 diabetes-associated single nucleotide polymorphisms in regions of pancreatic islet open chromatin at the JAZF1 locus. Diabetes. 2013;62:1756–62. https://doi.org/10.2337/db12-0972.CrossRefPubMedPubMedCentral

101.

Tuomi T, Nagorny CLF, Singh P, Bennet H, Yu Q, Alenkvist I, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab. 2016;23:1067–77. https://doi.org/10.1016/j.cmet.2016.04.009.CrossRefPubMed

102.

Gaulton KJ, Nammo T, Pasquali L, Simon JM, Giresi PG, Fogarty MP, et al. A map of open chromatin in human pancreatic islets. Nat Genet. 2010;42:255–9. https://doi.org/10.1038/ng.530.CrossRefPubMedPubMedCentral

Title: Pancreatic Islet Transcriptional Enhancers and Diabetes
Author: Inês Cebola
Publication date: 01-12-2019
Publisher: Springer US
Keyword: Type 2 Diabetes
Published in: Current Diabetes Reports / Issue 12/2019
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1230-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2019

Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes

Diagnostic Strategies for Gestational Diabetes Mellitus: Review of Current Evidence

Human Endogenous Retroviruses and Type 1 Diabetes

Organoids from the Human Fetal and Adult Pancreas

The Effects of Lifestyle and/or Vitamin D Supplementation Interventions on Pregnancy Outcomes: What Have We Learned from the DALI Studies?

Natural Alternative Sweeteners and Diabetes Management

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage